Skip to content

CagriSema: FDA approval status and what Novo Nordisk has reported

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

CagriSema is Novo Nordisk's investigational once-weekly injection. It is not FDA-approved, so it has no release date. Novo Nordisk filed a New Drug Application for weight management in December 2025 and has said a decision is expected in the fourth quarter of 2026. In REIMAGINE 2, the company reported weight loss of 14.2% at 68 weeks, against 10.2% with semaglutide 2.4 mg.

Source: Novo Nordisk

Key takeaways

  • CagriSema is not FDA-approved, and it has no US release date or price.
  • Novo Nordisk expects an FDA decision in the fourth quarter of 2026. That's timing, not a promise of approval.
  • The trial results here are the company's own reports, not FDA findings.
  • FDA says cagrilintide cannot be used in compounding, so a product sold as cagrilintide is not a legal option.
  • If you're weighing an approved medicine against waiting, talk it through with your prescriber.

Searches for a CagriSema release date are running ahead of the facts. A medicine gets a US release date after FDA approves it, and CagriSema is an investigational medicine under FDA review. This page sets out what Novo Nordisk has said and marks clearly what isn’t known. The information comes from Novo Nordisk announcements and FDA. Company statements are not FDA findings.

CagriSema FDA approval status

  • Not FDA-approved. Novo Nordisk calls CagriSema its “next-generation investigational obesity and diabetes treatment.”
  • Under FDA review for weight management. The company has said: “Novo filed a New Drug Application with the U.S. Food and Drug Administration in December 2025 for CagriSema for weight management.” It has also said it applied to Health Canada in the same month.
  • Decision timing, according to the company. “A decision is expected in Q4 2026.”

That last line is the closest thing to a date the company has given, so read it carefully. It’s the company’s expectation of when FDA will decide. It is not a prediction that the decision will be an approval, and it is not a launch date. Even after an approval, the manufacturer sets the date a medicine reaches pharmacies.

What CagriSema is

CagriSema is a once-weekly injection under the skin that combines two medicines at a fixed dose:

  • Cagrilintide, a long-acting amylin receptor agonist. Amylin is a hormone involved in appetite and digestion.
  • Semaglutide, a GLP-1 receptor agonist.

Semaglutide is already sold in three approved brands, Wegovy, Ozempic and Rybelsus, each with its own label and approved uses. Cagrilintide is not approved in any product. CagriSema as a combination has no label, so nothing on those three labels can be applied to it.

Novo Nordisk is studying CagriSema in two programs: REDEFINE, for adults with overweight or obesity, and REIMAGINE, for adults with type 2 diabetes. The FDA application covers weight management.

The CagriSema clinical trials behind the application

Novo Nordisk says the December 2025 submission was based on two pivotal trials, the main trials meant to support approval. Both ran for 68 weeks, and both tested once-weekly CagriSema 2.4 mg/2.4 mg. That figure names the group in the trial. It is not dosing guidance, and no approved dose exists.

  • REDEFINE 1. A Phase 3 trial of how well it works and how safe it is, in 3,417 adults with obesity, or overweight with one or more related health conditions, and without type 2 diabetes. It compared CagriSema with cagrilintide 2.4 mg alone, semaglutide 2.4 mg alone and placebo.
  • REDEFINE 2. A Phase 3 trial of how well it works and how safe it is, in 1,206 adults with type 2 diabetes and either obesity or overweight. It compared CagriSema with placebo.

Results Novo Nordisk has reported

REIMAGINE 2, reported February 2, 2026

This trial enrolled 2,728 adults with type 2 diabetes and compared CagriSema with semaglutide 2.4 mg. Novo Nordisk reported these results, on the basis that all people adhered to treatment:

  • Weight. From an average starting body weight of 101 kg, people treated with CagriSema achieved weight loss of 14.2% after 68 weeks, compared with 10.2% with semaglutide 2.4 mg.
  • Blood sugar. From an average starting HbA1c of 8.2%, HbA1c fell by 1.91 percentage points with CagriSema, compared with 1.76 with semaglutide 2.4 mg. HbA1c is a blood test that reflects average blood sugar over the past few months.

Novo Nordisk described both results as superior. Because this comparison is within one trial, it can be stated. Keep two limits in mind. The trial was in people with type 2 diabetes, and the weight management application rests on the REDEFINE trials, not this one.

A brain-imaging study, presented September 30, 2026

At the EASD 2026 meeting, Novo Nordisk presented a study in which changes seen on brain imaging were linked to a 22.4% reduction in body weight versus placebo at 52 weeks. That figure is an estimated treatment difference from a single study. The announcement’s headline also mentions reduced “food noise” and benefits in organ and bone health.

A higher-dose trial

Novo Nordisk said that in 2026 it started a Phase 3 trial of how well high-dose CagriSema 2.4 mg/7.2 mg works and how safe it is, in adults with obesity. That announcement included no results from it.

What we do not know

  • Whether FDA will approve CagriSema, and with what label.
  • The launch date, if it is approved.
  • The price, and whether insurers or Medicare would cover it.
  • The side effects as FDA would describe them. A label is where safety figures are set out.

If you read something that states any of these as settled, it’s ahead of the sources.

Can you buy CagriSema or cagrilintide?

Not legally outside a clinical trial. FDA states: “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.” Compounded drugs in general are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed.

We don’t name, link to or list prices for sellers of cagrilintide. The compounded GLP-1 page covers what FDA has said about unapproved products.

One related point comes from an approved label. The Wegovy label says using it with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. CagriSema contains semaglutide. If CagriSema is approved, how a prescriber would move someone from an existing semaglutide medicine to it will be a matter for its own label.

What happens next

The next milestone the company has named is the FDA decision it expects in the fourth quarter of 2026. FDA or Novo Nordisk would announce the outcome, and their own pages are the place to confirm it. The pipeline overview covers retatrutide and the other medicines people ask about.

Treatment decisions involve the medicines that are approved. The Wegovy guide covers the approved semaglutide medicine for weight, including its 7.2 mg dose, and the cost guide lists what the approved medicines cost. Whether to start an approved medicine or wait is for you and your prescriber to weigh.

Frequently asked questions

When will CagriSema be available?

There's no release date. CagriSema has to be approved by FDA before it can be sold in the US. Novo Nordisk has said a decision on its weight management application is expected in the fourth quarter of 2026. That's the company's expected timing for a decision, not a launch date.

Is CagriSema FDA-approved?

No. Novo Nordisk calls CagriSema an investigational treatment. It filed a New Drug Application with FDA in December 2025 for weight management. Separately, FDA says cagrilintide, one of its two components, is not a component of any FDA-approved drug and has not been found safe and effective for any condition.

What is CagriSema made of?

CagriSema is a fixed-dose combination of two medicines, given as one once-weekly injection under the skin. One is cagrilintide, a long-acting amylin receptor agonist. The other is semaglutide, a GLP-1 receptor agonist. Semaglutide on its own is the medicine in Wegovy, Ozempic and Rybelsus. Cagrilintide is not in any approved product.

What were the CagriSema trial results?

In REIMAGINE 2, a 68-week trial in 2,728 adults with type 2 diabetes, Novo Nordisk reported weight loss of 14.2% with CagriSema against 10.2% with semaglutide 2.4 mg. It also reported an HbA1c (average blood sugar) reduction of 1.91 percentage points against 1.76. Both figures assume all people adhered to treatment.

Can a pharmacy compound CagriSema or cagrilintide?

No. FDA says retatrutide and cagrilintide cannot be used in compounding under federal law. Any product sold as cagrilintide, or as a cagrilintide and semaglutide mix, is not an FDA-approved medicine and is not Novo Nordisk's investigational product. This site does not name or link to sellers of such products.

Sources (9)

  1. 1.
    Novo Nordisk: Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
    “Once-weekly subcutaneous CagriSema is being investigated by Novo as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is a fixed-dose combination of a long-acting amylin receptor agonist, cagrilintide, and a GLP-1 receptor agonist, semaglutide.”
  2. 2.
    Novo Nordisk: Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
    “Novo filed a New Drug Application with the U.S. Food and Drug Administration in December 2025 for CagriSema for weight management, demonstrating the company's commitment to obesity innovation. A decision is expected in Q4 2026.”
  3. 3.
    Novo Nordisk: Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
    “CagriSema for weight management was submitted to the US FDA in December 2025 based on the REDEFINE 1 and REDEFINE 2 pivotal trials.”
  4. 4.
    Novo Nordisk: Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
    “REDEFINE 1 – a 68-week efficacy and safety phase 3 trial of once-weekly CagriSema 2.4 mg/2.4 mg, cagrilintide 2.4 mg and semaglutide 2.4 mg versus placebo in 3,417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes. REDEFINE 2 – a 68-week efficacy and safety phase 3 trial of once-weekly CagriSema 2.4 mg/2.4 mg versus placebo in 1,206 adults with type 2 diabetes and either obesity or overweight.”
  5. 5.
    Novo Nordisk: Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
    “When evaluating the effects of treatment, if all people adhered to treatment, and from a mean HbA1c baseline of 8.2%, people treated with CagriSema 2.4 mg/2.4 mg achieved superior HbA1c reduction of 1.91%-points after 68 weeks compared to 1.76%-points with semaglutide 2.4 mg. From a mean baseline body weight of 101 kg, people treated with CagriSema 2.4 mg/2.4 mg achieved superior weight loss of 14.2% after 68 weeks compared to 10.2% with semaglutide 2.4 mg.”
  6. 6.
    Novo Nordisk: Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
    “CagriSema is Novo Nordisk’s next-generation investigational obesity and diabetes treatment. Novo Nordisk submitted an NDA for obesity to the US FDA and Health Canada in December 2025. In 2026, High-dose CagriSema 2.4 mg/7.2 mg, an efficacy and safety phase 3 trial, was initiated in adults with obesity. [...] In the study, also awarded a Best Abstract Award at EASD 2026, the improvements were also associated with a 22.4% reduction in body weight versus placebo at 52 weeks (estimated treatment difference at 52 weeks, p<0.0001).”
  7. 7.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.”
  8. 8.
    FDA: Compounding and the FDA: Questions and Answers
    “Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. Consumers and health care professionals rely on FDA’s drug approval process for verification of safety, effectiveness and quality.”
  9. 9.
    FDA label (DailyMed): Wegovy prescribing information, section 1
    “Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”